The $30 million net proceeds from the placement will allow the company to advance its clinical pipeline, Cue said. ・Cue also announced it has obtained an exclusive license from Ascendant Health ...

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the ...

Cue Biopharma Inc. CUE shares surged 67.57% overnight to $24.70 on Thursday after the company simultaneously announced a $30 ...

Novel dual-mechanism anti-IgE antibody designed to improve upon existing and emerging therapies for IgE-mediated diseases Cue ...

Cue Biopharma named Shao-Lee Lin as its chief executive officer. Lin succeeds Lucinda Warren, who held the CEO role on an interim basis. Lin was previously founder and CEO of biotechnology company ...

Cue Biopharma Inc. (NASDAQ:CUE) is one of the 10 Unstoppable Stocks That Could Double Your Money.

Preclinical milestone for selection and approval of first compound for lead optimization has been achievedFurther development validates the ...

BOSTON, June 24, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and ...

With the Pixel 10 series, Google has revealed a new AI feature called “Magic Cue.” Magic Cue watches your screen and offers suggestions by pulling relevant information from multiple apps. It currently ...